<DOC>
	<DOCNO>NCT00377234</DOCNO>
	<brief_summary>This 2 arm crossover study evaluate patient report preference either monthly Boniva ( 150mg p.o . ) weekly risedronate ( 35mg p.o. ) . Patients post-menopausal osteoporosis randomize receive Boniva 3 calendar month risedronate 12 week ; cross receive alternative treatment 12 weeks/3 month . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Comparing Monthly Boniva ( Ibandronate ) Weekly Risedronate Women With Post-Menopausal Osteoporosis .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>ambulatory woman postmenopausal osteoporosis ; patient bisphosphonatenaive , previously receive oral daily i.v . bisphosphonate therapy ( fulfil certain criterion detail protocol ) . malignant disease diagnose within previous 10 year ( except successfully resect basal cell cancer ; ) breast cancer within previous 20 year ; inability stand sit upright least 60 minute ; disease/disorder/treatment drug know influence bone metabolism .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>